RELAPSED/REFRACTORY MULTIPLE MYELOMA
Clinical trials for RELAPSED/REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a twice-a-month myeloma drug work just as well every 6 weeks?
Disease control Not yet recruitingThis study tests whether a drug called belantamab mafodotin, given with a steroid, can be safely used in community clinics for people with advanced multiple myeloma that has not responded to at least four prior treatments. The drug was previously approved but later withdrawn from…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Cristiana Costa Chase, DO • Aim: Disease control
Last updated May 17, 2026 08:48 UTC
-
Engineered immune cells take aim at Hard-to-Treat myeloma
Disease control Not yet recruitingThis early-phase study tests a new treatment for people with a type of multiple myeloma that has returned or not responded to standard therapies. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The main goals ar…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Peter MacCallum Cancer Centre, Australia • Aim: Disease control
Last updated May 17, 2026 08:47 UTC
-
New CAR T-Cell therapy takes on Hard-to-Treat blood cancer
Disease control Not yet recruitingThis study tests a new treatment called Equecabtagene autoleucel for people with multiple myeloma that has come back or stopped responding to standard therapies. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The goal is to control th…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Nanjing IASO Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 08:46 UTC
-
New hope for Hard-to-Treat myeloma: early trial launches
Disease control Not yet recruitingThis early-stage study tests a new drug, RO7851624, in 160 people with multiple myeloma that has returned or not responded to standard treatments. The main goal is to check the drug's safety and how the body processes it. Participants must have tried several prior therapies and h…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated May 15, 2026 12:07 UTC
-
New CAR-T therapy targets Hard-to-Treat blood cancer
Disease control Not yet recruitingThis early study tests a new type of CAR-T cell therapy (BCMA-GPRC5D) in 10 adults with relapsed/refractory multiple myeloma who have already tried at least three prior treatments. The therapy uses the patient's own immune cells, modified to attack two cancer targets, and is give…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: NA • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New hope for Tough-to-Treat myeloma: experimental drug SG2918 enters human trials
Disease control Not yet recruitingThis early-stage study tests a new drug called SG2918 in 40 people whose multiple myeloma has returned or not responded to prior treatments. The main goal is to check the drug's safety and how well the body tolerates it. Researchers will also measure how the drug moves through th…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated May 11, 2026 20:51 UTC